2015
![Original INNODIA logo 3](/sites/default/files/styles/small/public/2023-04/INNODIA%20Logo%20high%20resolution.png?itok=mBxymcKO)
The INNODIA_Project is launched thanks to funds provided by the European Commission, The Hemsley Charitable Trust, Breakthrough T1D, and EFPIA partners as a global partnership between academic institutes, industry and patients, gathering their knowledge and experience, with one common goal: eradicate type 1 diabetes.
2019
![HARVEST](/sites/default/files/styles/small/public/2023-04/HARVEST.jpg?itok=nDmdv7er)
Building on the strong foundation of the INNODIA_Project, the consortium receives additional funds to start another ambitious project, called INNODIA HARVEST.
2020
![EMA](/sites/default/files/styles/small/public/2023-04/EMA_logo_transparent_background%20%28002%29.png?itok=4FVNTF45)
The INNODIA_Projects receive postive advice for a Master Protocol; a unifying study design undertaken to improve the standardisation and speed of Phase 2 studies to determine safety and efficacy of established, novel and re-purposed therapies halting the decline of beta cell function in people with newly diagnosed type 1 diabetes.
2020
![Start CT's our story 2020](/sites/default/files/styles/small/public/2023-04/Start%20CT%27s%20our%20story%202020.jpg?itok=Xk_f6OOY)
Another milestone is the start of 4 intervention clinical trials (2 investigator-initated and 2 pharma-driven): a key step towards the evidence that the consortium was taken to a next level by going from biomarker discovery to development of a successful network facilitating intervention studies in type 1 diabetes in Europe.
2021
![Publications](/sites/default/files/styles/small/public/2023-04/Publications.jpg?itok=IE0ll3cX)
The INNODIA_Projects’ partners reach more than 100 joint peer-reviewed publications. The recruitment target of newly diagnosed people with type 1 diabetes in the observational study is also achieved.
2022
![Balance iVZW founded](/sites/default/files/styles/small/public/2023-04/Balance%20system%20_0.jpg?itok=MlUSORLv)
To guarantee continuity and expansion of the successful research and clinical network established under the INNODIA_Projects’ funding period, INNODIA is transformed into a legal entity (iVZW - international non-profit organisation) with the consolidated mission to accelerate the development of new cures and promote disease modifying therapies for people living with type 1 diabetes, everywhere.
2023
![Innodia png](/sites/default/files/styles/small/public/2023-04/innodia-logo-20233x.png?itok=B3AEErL3)
By hiring its first Managing Director, INNODIA starts taking shape.
Find out more about the INNODIA_Projects
INNODIA launch supported by:
![Helmsley](/sites/default/files/styles/brand/public/2023-04/April%202023%20helmsley%20high%20resolution.jpg?itok=OPd3njj4)
![Novo Nordisk](/sites/default/files/styles/brand/public/2023-04/NNF-INT_logo_tagline_blue_RGB_solid_0.png?itok=6IE2Lc0o)
![](/sites/default/files/styles/brand/public/2024-06/Logo%20white.png?itok=HsE7rrHi)
Interested in our story or in search for guidance?
![Interested in our story](/sites/default/files/styles/small/public/2023-04/Interested%20in%20our%20story.jpg?itok=PxTRph7O)